Is Boryung Pharmaceutical profitable in 2026?

Yes but weakening. Boryung's FY2025 revenue was flat at about 1.02 trillion won (plus 0.03 percent) while operating profit and net income fell roughly 7.65 percent, per stockanalysis.com data as of February 19, 2026, following FY2024's 70.5 billion won operating profit.

What is Boryung's biggest competitor?

Yuhan Corporation leads Korean traditional pharma with 2.19 trillion won FY2025 revenue, ahead of Hanmi Pharmaceutical (1.5475 trillion won, strongest margins and Merck out-licensing), both outranking Boryung's roughly 1.02 trillion won, per Chosun Biz on February 11, 2026.

Could AI replace Boryung Pharmaceutical?

Unlikely directly. Boryung's revenue relies on legacy-brand acquisitions, generics, manufacturing licenses like its Ansan penicillin plant (about 60 percent of Korea's oral penicillin output), and NHI reimbursement listings, not proprietary drug-discovery AI, per Korea Biomed reporting from March 31, 2025.

Who owns Boryung Pharmaceutical?

Boryung is publicly listed on the Korea Exchange (ticker 003850), controlled by the Kim founding family via Boryung Partners Co., which bought 18.1 million shares for about 175 billion won in November 2024. Chairman Jay Kim became sole CEO after a February 2025 board decision.

What happened with Boryung's Kanarb price-cut lawsuit?

Boryung lost its first-instance suit against a government-mandated price cut on its flagship hypertension drug Kanarb (over 180 billion won in annual sales) in a ruling reported February 19, 2026; Korean courts have similarly sided against Dong-A ST and Daewon Pharm, and Boryung's appeal is pending.

Why is Boryung investing in space medicine?

Boryung has put over 60 to 90 billion won into 11 space-medicine projects including Axiom Space and Intuitive Machines, with CEO Jay Kim taking a board seat at Axiom, but its BRAX Space joint venture generated only 930,000 won in related-party sales in Q1 2026, per Korea Biomed on June 11, 2026.

Pharma and healthcare groups · South Korea

Boryung Pharmaceutical

boryung.co.kr ↗

South Korean drugmaker known for hypertension drug Kanarb, branching into space medicine.

Defensible for now

Assessed 25 July 2026 · Evidence as of 25 July 2026

Real protection, with named pressure against it.

On the recordSince 25 July 2026 · Checkable from within 6 to 12 months of Feb 2026 · Every call on the record Checkpoint: Kanarb price-cut appeal ruling

The call

Boryung's core pharma business stays profitable but stalling under price cuts, while its cash funds space-medicine bets that have not yet paid off.

Boryung makes and sells pharmaceutical drugs in South Korea, with particularly strong control over penicillin production and a popular blood pressure medicine called Kanarb. The company is hard to displace because it has deep relationships with Korea's health insurance system and owns factories that produce about 60 percent of the country's penicillin, but the government keeps cutting the prices it can charge for medicines, which squeezes profits. The company recently lost a court fight over Kanarb's price and is betting big money on space medicine experiments that barely generate any sales yet, so the real question is whether revenue growth and profits can recover, or whether the company slides into a long decline.

Why

AI pressure: Isomorphic Labs and other AI drug-discovery labs. AI drug discovery could help rivals find new molecules faster, but does not directly threaten Boryung's branded hypertension and distribution business yet. Could AI do the core job? Unlikely.

Bigger players: Korean National Health Insurance pricing regulator. Government-mandated price cuts already hit Kanarb, Boryung's biggest drug, following precedent losses by Dong-A ST and Daewon. Could a giant copy it? Probably.

What protects it. Decades of KNHI reimbursement approval, a penicillin plant with about 60 percent domestic share, and a dedicated cytotoxic drug campus.

What would change this call

Outcome of Boryung's appeal on the Kanarb price-cut ruling within 6-12 months. Losing confirms structural margin erosion in its flagship drug franchise.
FY2026 full-year revenue and operating profit figures versus FY2025. A second straight year of profit decline would show the core business weakening.
Whether Taxotere/Ditaxel and space-medicine ventures report material revenue growth. Would show if capital diverted from the core pharma business is paying off.

Key numbers

FY2024 revenue crossed 1.02 trillion won, up 18.3 percent (2025-02-04)
FY2025 revenue nearly flat, up just 0.03 percent (2026-02-19)
Kanarb sales fell from over 150bn won in 2023 to 136.2bn won in 2024 (2025-03-31)

Named risks

Kanarb price-cut appeal loss could permanently cut core drug revenue after 2026-02 first-instance defeat. Severity: high
FY2025 flat revenue plus declining profit signals possible multi-year stagnation of core pharma business. Severity: medium
Speculative space-medicine bets (60-90bn won) show minimal returns, BRAX Space sales only 930,000 won Q1 2026. Severity: medium
Mandated Ditaxel divestiture from KFTC could complicate integration of newly acquired Taxotere rights. Severity: medium
December 2025 data breach exposed 8 million plus internal messages and employee records, reputational exposure. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Yuhan Corporation	losing to	Yuhan posted 2.19tn won FY2025 revenue versus Boryung's 1.02tn, reported 2026-02-11
Hanmi Pharmaceutical	losing to	Hanmi had 1.5475tn won revenue and strongest operating margin plus Merck out-licensing, 2026-02-11
Dong-A ST	contesting	Both lost government price-cut lawsuits, ruling confirmed 2026-05-27, Boryung appeal pending
SK Biopharm	losing to	Named a Nature Innovation Leader in K-Bio ranking, 2026-07-02, Boryung absent from listing
HK inno.N	contesting	Co-promotion partner for Canav/K-CAB but also crossed 1tn won revenue itself in 2025

Questions people ask

Is Boryung Pharmaceutical profitable in 2026?: Yes but weakening. Boryung's FY2025 revenue was flat at about 1.02 trillion won (plus 0.03 percent) while operating profit and net income fell roughly 7.65 percent, per stockanalysis.com data as of February 19, 2026, following FY2024's 70.5 billion won operating profit.
What is Boryung's biggest competitor?: Yuhan Corporation leads Korean traditional pharma with 2.19 trillion won FY2025 revenue, ahead of Hanmi Pharmaceutical (1.5475 trillion won, strongest margins and Merck out-licensing), both outranking Boryung's roughly 1.02 trillion won, per Chosun Biz on February 11, 2026.
Could AI replace Boryung Pharmaceutical?: Unlikely directly. Boryung's revenue relies on legacy-brand acquisitions, generics, manufacturing licenses like its Ansan penicillin plant (about 60 percent of Korea's oral penicillin output), and NHI reimbursement listings, not proprietary drug-discovery AI, per Korea Biomed reporting from March 31, 2025.
Who owns Boryung Pharmaceutical?: Boryung is publicly listed on the Korea Exchange (ticker 003850), controlled by the Kim founding family via Boryung Partners Co., which bought 18.1 million shares for about 175 billion won in November 2024. Chairman Jay Kim became sole CEO after a February 2025 board decision.
What happened with Boryung's Kanarb price-cut lawsuit?: Boryung lost its first-instance suit against a government-mandated price cut on its flagship hypertension drug Kanarb (over 180 billion won in annual sales) in a ruling reported February 19, 2026; Korean courts have similarly sided against Dong-A ST and Daewon Pharm, and Boryung's appeal is pending.
Why is Boryung investing in space medicine?: Boryung has put over 60 to 90 billion won into 11 space-medicine projects including Axiom Space and Intuitive Machines, with CEO Jay Kim taking a board seat at Axiom, but its BRAX Space joint venture generated only 930,000 won in related-party sales in Q1 2026, per Korea Biomed on June 11, 2026.

Timeline

2026-06-04KFTC conditionally approves Taxotere deal, orders Boryung to divest competing Ditaxel drug
2026-05-27Reports confirm Boryung among pharma firms losing price-cut lawsuits alongside Dong-A ST, Daewon
2026-04-30Q1 2026 results: revenue 255.35bn won, operating profit 20.15bn won, net income 41.4bn won
2026-02-19Report: Kanarb price cut halts Boryung's 8-year growth streak, FY2025 revenue nearly flat
2026-02-11Businesskorea reports eight Korean pharma firms including Boryung topped 1tn won FY2025 revenue
2025-12-04Exposed MongoDB database leaks 8 million plus internal chat messages, 3,500 employee records
2025-10-30Boryung signs CDMO deal with Zuellig Pharma to supply Alimta across 7 Southeast Asian countries
2025-09-30Boryung agrees to acquire Sanofi's global Taxotere rights for up to 175 million euros
2025-02-28Jay Kim becomes sole CEO after Jang Doo-hyun's resignation
2025-02-04Boryung reports FY2024 revenue of 1.0171tn won, first Korean traditional pharma to cross 1tn won

Revision history

25 July 2026

First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.

In the same band

Zoetis Boston Scientific Becton Dickinson

More in Pharma and healthcare groups →

Sources